Firma Supports Decentralized Alzheimer’s Diagnostic Clinical Trial

||Firma Supports Decentralized Alzheimer’s Diagnostic Clinical Trial

Firma Supports Decentralized Alzheimer’s Diagnostic Clinical Trial

C2N Diagnostics and Firma Clinical teamed up to create a successful, decentralized Alzheimer’s diagnostic clinical trial. Firma was contracted to lead the recruitment effort (ensuring the eligibility of participants and performing a fully compliant informed consent process), collect and process about 500 blood samples from participants in their homes, and ship the samples to C2N for testing.

Read more HERE  about this successful decentralized study in an Applied Clinical Trials article written by Melissa Nezos, Firma’s VP of Clinical Operations.

2020-08-13T16:39:29+00:00August 13th, 2020|Categories: News & Media|Tags: , |